Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mu... Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. Mehr anzeigen
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics PR Newswire NORTH CHICAGO, Ill., Jan. 23, 2025 Monopar's pipeline includes clinical-stage radiopharmaceuticals...
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 11.66 | 40.2068965517 | 29 | 41.94 | 28.6505 | 74858 | 37.55332627 | CS |
| 4 | 15.92 | 64.3492320129 | 24.74 | 41.94 | 21 | 52586 | 28.92975347 | CS |
| 12 | 26.32 | 183.542538354 | 14.34 | 41.94 | 13.94 | 95294 | 21.63144442 | CS |
| 26 | 37.01 | 1013.97260274 | 3.65 | 41.94 | 1.719 | 653420 | 13.38158558 | CS |
| 52 | 38.8365 | 2129.77789964 | 1.8235 | 41.94 | 1.545 | 1724206 | 6.58794038 | CS |
| 156 | 26.56 | 188.368794326 | 14.1 | 41.94 | 1.3695 | 714189 | 6.03607621 | CS |
| 260 | -41.34 | -50.4146341463 | 82 | 102.5 | 1.3695 | 456855 | 8.28465549 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
